Evidence for lecanemab in early Alzheimer’s disease
Overview of: van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388:9–21
- Health Care Quality, Access, and Evaluation
- Drug-Related Side Effects and Adverse Reactions
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.